Sargramostim for Myeloid Dendritic Cell Deficiency
Status:
Terminated
Trial end date:
2018-09-17
Target enrollment:
Participant gender:
Summary
The study will determine whether administration of sargramostim will improve myeloid
dendritic cell deficiency in various study groups, including healthy subjects and patients
with chronic kidney disease, including those with kidney transplants.